Abstract. The appearance of anti-human growth hormone (hGH) and anti-non-hGHs antibodies in 27 patients with idiopathic hypopituitarism, treated for periods of 6\p=m-\18months with three different preparations of hGH, was investigated. The preparations induced antibodies to GH in 21 out of the 27 patients: 10 patients produced exclusively an anti-non-hGH response, whereas 11 generated both anti \x=req-\ non-hGH and anti-hGH antibodies. The levels of antibodies against hGH had low correlation with decreased growth velocity, whereas those for the antibodies against non-hGHs did not correlate with decreased growth velocity. We 
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We recently described a type of humoral 'heterologous' immunity observed in human hypopituitary patients therapeutically treated with human growth hormone (hGH) (Poskus et al. 1982 (1966) and pubertal stage was determined accord¬ ing to the criteria described by Tanner ( 1964 (Frasier et al. 1969) .
The sera from 6 of the patients (No.s 1, 2, 4, 5, 6 and 7) included in our previous report (Poskus et al. 1982) were used here to extend the specificity studies.
Methods
Bovine (b), ovine (o) and equine (e) GHs used for labelling and/or displacement assays were prepared in our laboratory as described previously (Poskus et al. 1982 (Roth 1975 (Fig. 1, left panel) . On the other hand, 10 out of 21 antibody bearing patients presented only anti-bGH reactivity (Fig. 1, right (Fig. 4) (Poskus et al. 1982) . In this paper we report a longitudinal study in patients under long-term therapy of the appearance and variation with time of the anti-non-hGHs and anti-hGH activities in their sera.
We define the titre of the sera in liquid phase RIA as the maximum serum dilution yielding signi¬ ficant binding of the tracer as compared with the non-specific controls made with appropriate dilu¬ tions of normal human sera. Equivalent criteria for significant binding inhibition were employed when faster solid phase competition tests were used. Alternative criteria have been employed by other investigators. For instance, Milner et al. (1979) and Illig (1970) considered the titre of the sera to be the highest dilution required to yield a 25% or 50%
[12SI]hGH binding, respectively. The employment of these criteria results in an apparently lower incidence of antibody formation in their patients.
The information collected in Table 2 indicates that anti-non-hGH antibodies appear more fre¬ quently than anti-hGH antibodies (incidence 78% and 67%, respectively). None of the three pre¬ parations of hGH is totally free of immunogenic activity. On the other hand, no characteristic pattern was detected with respect to the first in¬ duced antibody population or with respect to the intensity of the response reached. In addition, independently of its specificity, the induced and-body seems in some instances to be of a transient nature ( Table 2 ). (Poskus et al. 1982) . Nevertheless, such anti-bGH antibodies had a high affinity (K~I O10-1011 NT1) for the bGH antigen. The binding capacities were also estimated for all these components (Poskus et al. 1982 Hence, the titration data in Table 2 Although the effect of GH antibodies on the treatment of hypopituitary patients is still obscure, any future research on this relationship should take all the participant antibodies into considera¬ tion.
Titration curves obtained with labelled h, b, e and pGH and 6 selected sera gave the relative reactivities of both hGH and non-hGH antibodies (Fig. 2) . The curves clearly demonstrate that the anti-hGH antibodies appear in a pattern fairly independent of that of all the anti-non-hGH anti¬ bodies.
Labelled pGH was included in this study to confirm that the anti-pGH reactivity found in a high proportion of hGH-treated patients (Murthy & McGarry 1971) is probably due to the same antibody population reacting with b and eGHs.
The specificity of both types of antibodies was assessed by competition experiments (Figs. 3 and  4) . Displacement curves showed a wide spectrum of cross-reactivity of the antibodies to non-hGHs tested against 6 different mammalian GHs. On the other hand, the reduced specificity exhibited by the anti-hGH antibodies in serum should be noted.
Independently of the actual reasons for the 'heterologous' antibody induction, it is noteworthy that hGH exhibits a very different behaviour as immunogen and as antigen. In fact, in some patients (see Fig. 4 
